American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 6(66), 2022
DOI: 10.1128/aac.00254-22
Full text: Download
The objective of this study was to describe the population pharmacokinetics of remdesivir and GS-441524 in hospitalized coronavirus disease 2019 (COVID-19) patients. A prospective observational pharmacokinetic study was performed in non-critically ill hospitalized COVID-19 patients with hypoxemia.